Endo pays $2.3m to settle states antitrust claims
Ireland-headquartered Endo Pharmaceuticals agreed to pay $2.3 million to 18 states late last week, settling allegations that the drugmaker paid a competitor to keep a generic version of pain relief drug Lidoderm off the market.
Eversheds opens San Diego office
Eversheds Sutherland has continued its expansion in the US, with the opening of a San Diego office and the addition of three IP litigators.
USPTO grants ‘CRISPR search engine’ patent
The US Patent and Trademark Office has granted Mammoth Biosciences applications for two patents covering what the company claims are “first-of-their-kind” CRISPR diagnostic techniques.
Counterfeit HPV vaccines seized in Hong Kong
Hong Kong customs authorities have carried out a series of raids resulting in the seizure of counterfeit vaccines worth over HKD $1 million, some containing poison.
Johnson & Johnson braces for Q3 sales dip as generics bite
Johnson & Johnson has warned that strong competition from generic drugs could impact the company’s figures for the rest of the year.
Medical laser makers settle microneedle dispute
Massachusetts-based medical laser company Candela and Israeli medical devices manufacturer Lumenis have settled all outstanding patent litigation between the two parties.
Delhi court rejects Bayer injunction against Natco Pharma generic
India’s Delhi High Court has dismissed a petition for an injunction by German pharma company Bayer against an Indian competitor.
Gilead enters $5bn R&D deal with Galapagos
Gilead will pay more than $5 billion as part of a collaborative research and development agreement with Belgian-Dutch pharmaceutical company Galapagos.
Indivior appeal fails to stop generic opioid addiction challenge
The US Court of Appeals for the Federal Circuit has upheld an earlier ruling that Indivior cannot stop two competitors from making a generic version of one of its drugs.
German Court rules Sanofi’s Praluent infringes Amgen patent
A German court has found that Sanofi’s high-cholesterol treatment, Praluent, infringes one of Amgen’s patents.
